ECP
MRVI icon

Epacria Capital Partners’s Maravai LifeSciences MRVI Stock Holding History

Epacria Capital Partners’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$283K Hold
100,078
– – 0.22% 27
2025
Q4 		$325K Hold
100,078
– – 0.26% 29
2025
Q3 		$287K Buy
100,078
+6,384
+7% +$16.3K 0.23% 28
2025
Q2 		$226K Buy
93,694
+38,264
+69% +$80.4K 0.19% 32
2025
Q1 		$122K Buy
+55,430
New +$219K 0.1% 39

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Epacria Capital Partners's MRVI Position: Q1 2026 in Review

Epacria Capital Partners held its Maravai LifeSciences (MRVI) position steady in Q1 2026 at 100,078 shares worth $283K. The position accounts for 0.22% of the portfolio, ranked #27.

Epacria Capital Partners first reported a position in MRVI in Q1 2025 and has held it in 5 quarters since. The position peaked at $325K in Q4 2025. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • Epacria Capital Partners held 100,078 shares of Maravai LifeSciences worth $283K as of Q1 2026.
  • Epacria Capital Partners left its Maravai LifeSciences share count unchanged in Q1 2026.
  • Maravai LifeSciences made up 0.22% of Epacria Capital Partners's portfolio in Q1 2026, its #27 holding.
  • Epacria Capital Partners first reported a position in Maravai LifeSciences in Q1 2025 and has held it in 5 quarters since.
  • Epacria Capital Partners's Maravai LifeSciences position peaked at $325K in Q4 2025.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Epacria Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.